Background {#Sec1}
==========

Perioperative organ protection has always been a critical issue for both anesthesiologists and surgeons. Neurological and cardiac outcome severely affects postoperative morbidity and mortality. With the development of the modern medicine, the population of aging patients with ischemic heart and brain diseases has significantly increased. A large number of patients, who have already suffered heart attack or cerebral stoke, have to risk the ischemia--reperfusion (I/R) damage again in surgical operations, the results could be devastating.Fig. 1Similar molecular signaling pathways of anti-apoptotic effect in cardiomyocytes and neurons induced by APC

Cardiomyocytes and neurons are both highly hypoxia-sensitive cells with, however, very different properties. Myocytes are muscle cells and responsible for the systolic and diastolic functions. They are regulated mainly by beta adrenergic system. Neurons, on the contrary, are electrically excitable cells. They connect to each other and transfer electrical and chemical signals via synapse. The two systems are separated from each other by blood--brain-barrier, which has highly selective permeability. Interestingly, the ischemic conditioning phenomenon has been demonstrated in both organs. Volatile anesthetic (VA)-induced preconditioning contributes to both cardiac and cerebral protection in the I/R injury \[[@CR1], [@CR2]\]. Sevoflurane-, isoflurane- and desflurane-induced preconditioning have been confirmed to be capable of reducing the infarct size, improving perioperative cardiac function significantly \[[@CR3], [@CR4]\]. In neurological experiments, these medical gases also exert their remarkable protective properties against cerebral ischemic injury \[[@CR5]\]. How could APC achieve 'multiorgan' protection? A large number of studies have been applied to understand this essential phenomenon. The aim of this review is to provide an overview and compare the molecular actions and subsequent cellular signaling cascade mediated by APC in these two totally different systems.

Mitochondrial function {#Sec2}
======================

mK~ATP~ channels {#Sec3}
----------------

In cardiomyocytes and neurons, mitochondria produce the majority of cellular adenosine triphosphate (ATP) and pathological reactive oxygen species (ROS) during I/R injury \[[@CR6], [@CR7]\]. They also play a key role in VA-induced preconditioning. Numerous studies have demonstrated that sevoflurane and other VAs protect the myocardium and brain during I/R injury via the mitochondrial ATP-sensitive potassium (mK~ATP~) channels, opening of mK~ATP~ channels results in potassium influx, slowing of calcium overload in the mitochondria, the production of reactive oxygen species and the activation of multiple downstream kinases and molecular cascades of cardiac protection, and this has been considered as a critical step in APC \[[@CR8], [@CR9]\]. It is verified that isoflurane can directly activate the human cardiac mK~ATP~ channels in vitro. ATP-sensitive K^+^ currents were significantly increased after isoflurane exposure, and this effect was completely abolished by mK~ATP~ channels blocker 5-hydroxydecanoate (5-HD) \[[@CR10]\]. Riess et al. provided the first evidence that sevoflurane is able to prevent mitochondrial matrix volume (MMV) contraction during ischemia, and this effect is mediated via mK~ATP~ channel opening \[[@CR11]\]. Among all the signaling kinases which are involved in cardiovascular functions, protein kinase C (PKC) and its subgroup PKCε are believed to be key signaling pathway associated with mK~ATP~ channel-mediated cardiac protection \[[@CR8], [@CR12], [@CR13]\]. Wang et al. demonstrated that sevoflurane preconditioning exhibits a delayed cardioprotection against I/R injury by increasing PKCε phosphorylation, and this effect is inhibited by mK~ATP~ channel blocker 5-HD \[[@CR14]\]. Similar effects were also reported by Kaneda et al. \[[@CR15]\] and Weber et al. \[[@CR16]\] confirming the key role of PKCε/mK~ATP~ signaling pathway in cardiac protective effect induced by APC.

Mitochondrial K~ATP~ channel proteins, which are partially purified from rat brain mitochondria, exhibit ligand-binding properties similar to those of heart mK~ATP~ channels, and the amount of mK~ATP~ channels in brain seems to be much higher than in the heart, suggesting the crucial role of mK~ATP~ channel in central nervous system \[[@CR17]\]. Numerous studies have proved that VA preconditioning provides neuroprotection via mK~ATP~ channel both in vivo and in vitro. Kehl et al. demonstrated that the preconditioning induced by sevoflurane was abolished by 5HD, a mK~ATP~ channel blocker, in rat hippocampal slices \[[@CR18]\]. Likewise, it was observed that the opening of mK~ATP~ channel mimicked delayed preconditioning induced by sevoflurane, whereas sevoflurane postconditioning was also blocked by 5-HD given at the end of ischemia \[[@CR19]\]. Interestingly, it was also reported for the first time by the same research team \[[@CR19]\] that neuroprotective effects mediated by sevoflurane were observed when sevoflurane was given at the onset of reperfusion, and this effect was lost when it is given 5 min after the onset of reperfusion, indicating the time, duration and other factors also associate and play potential relevance in APC. Moreover, it is found recently that the P38 phosphorylation was decreased after the administration of 5-HD, suggesting that mK~ATP~ channel opening and p38 phosphorylation are both involved sevoflurane-induced preconditioning and p38 MAPK activation may be a downstream of opening mK~ATP~ channels \[[@CR20]\]. Similar to cardioprotection, PKCε is also involved in APC-mediated neuroprotection. Ye et al. demonstrated that application of 5-HD 30 min before sevoflurane exposure could not only attenuate its beneficial effects in reducing neurological deficit scores and brain infarct volume, but also inhibit the translocation of PKC ε to the membrane fraction at 24 h after reperfusion \[[@CR21]\]. This result also indicates the role of PKC ε as the upstream target of mK~ATP~ channels and thus the similar cell signal pathway in APC-mediated protective effects in both cardiac and neural system.

mPTP {#Sec4}
----

The mitochondrial permeability transition with the formation of mitochondrial permeability transition pore (mPTP) has been identified as a key mediator in the process of mitochondrial dysfunction. The formation of mPTP could be induced under the pathological conditions, such as Ca^2+^ overload and oxidative stress due to ischemia or chronic heart failure, and the opening of mPTP causes mitochondrial dysfunction with lipid peroxidation, ATP hydrolysis, matrix swelling and ultimately cell death \[[@CR22], [@CR23]\]. Moreover, using pharmacological inhibitor of mPTP cyclosporine A (CsA) demonstrated protective effects against myocardial ischemic--reperfusion injury through reducing the infarct size and apoptotic cardiomyocyte death \[[@CR24]\]. Accumulating data have shown that inhibition opening of mPTP is related to volatile anesthetic-induced preconditioning: Pravdic et al. reported that isoflurane preconditioning delays mPTP opening under conditions of oxidative stress in rat cardiomyocytes \[[@CR25]\]; similar effect of isoflurane preconditioning was confirmed again in a recent study by Sepac et al. with cardiomyocytes derived from human embryonic stem cells (hESC), mPTP opening time of cardiomyocytes was significantly delayed after 15-min pretreatment with 0.5 mM isoflurane \[[@CR26]\]; Onishi et al. demonstrated the direct evidence that sevoflurane preconditioning, similar to CsA, inhibits calcium-induced mPTP opening by increasing the threshold, and this cardioprotective effect is mediated by inhibition of glycogen synthase kinase 3ß (GSK-3β) by phosphorylation through phosphatidylinositide 3-kinases/protein kinase B (PI3K/AKt) pathway \[[@CR27]\].

Mitochondrial dysfunction contributes to neurologic disorders, including neurodegenerative diseases and stroke, where, similar to cardiac I/R injury, excessive Ca^2+^ uptake can activate the opening of mPTP, which causes uncoupled ATP synthesis, following with neuronal death \[[@CR28], [@CR29]\]. Recent studies confirmed that inhibition of mPTP opening is also one of the most important cellular mechanisms of APC-induced neuroprotection. It is demonstrated by Ye's group that sevoflurane preconditioning protects mitochondria from cerebral I/R injury by hyperpolarizing mitochondrial membrane potential in ischemic brain issue and inhibiting Ca^2+^-induced mitochondrial permeability transition. Ischemic rats pretreated with sevoflurane exhibited a significantly diminished neurological deficit, and the infarct volume was reduced by 34% \[[@CR30]\].

ROS {#Sec5}
---

Reactive oxygen species were known to be released under the oxidative stress. Overproduction of ROS can result in cellular dysfunction and has a key role in various chronic diseases such as cardiac vascular diseases and neurodegenerative diseases. In I/R injury, large amounts of ROS are released during reperfusion, produce oxidative damage to lipids, proteins, nucleic acids and finally severe tissue damage \[[@CR7], [@CR31], [@CR32]\]. Recent evidence suggests that, in contrast, small amounts of ROS released from mitochondria could induce preconditioning and contribute to cardioprotection; this effect could be abolished with ROS scavengers \[[@CR33], [@CR34]\]. VAs trigger the production of a small amount of ROS, which appear to be critical events at the onset of cell signaling cascade of preconditioning against myocardial injury \[[@CR6], [@CR33], [@CR35]\]. Pretreatment with sevoflurane at 2% or desflurane at 7% before a 30-min hypoxic period enhanced the recovery of myocardial contraction of human atrial trabeculae; however, this function was inhibited by *N*-\[2-mercaptopropionyl\]-glycine (MPG), a ROS scavenger, indicating the role of ROS in sevoflurane- and desflurane-induced preconditioning against cardiac I/R injury \[[@CR36]\]. Isoflurane was demonstrated to have the ability to enhance the production of ROS in hESC-derived cardiomyocytes \[[@CR26]\]. The in vitro study of Sedlic et al. showed that the rate of ROS generation was significantly increased during the application of desflurane or sevoflurane, and after anesthetic washout, the rate of ROS production was decreased \[[@CR37]\]. The ROS production elicited by VAs might mediate mitochondrial uncoupling in APC signaling cascade.

In central nervous system, ROS was also demonstrated to be involved in VA-preconditioning-induced neuroprotection. ROS generation and its role in triggering of APC was examined by Velly et al. on mixed cortical neuronal--glial cell cultures subjected to transient oxygen--glucose deprivation (OGD) \[[@CR38]\]. The result showed that sevoflurane exposure during preconditioning induced a significant increase in ROS levels, which was prevented by ROS scavengers. In a rabbit spinal cord ischemic injury model, isoflurane demonstrated a delayed neuroprotective effect via the release of free radicals \[[@CR39]\]. It has also been proved in vivo with a rat middle cerebral artery occlusion (MCAO) model in a recent study, that the initial oxidative stress generated by sevoflurane preconditioning may trigger cascades that finally lead to ischemic tolerance \[[@CR40]\]. However, although transient production of ROS is necessary for APC, chronic oxidative stress still appears to result in mitochondrial damage and cell death, thus decrease cardioprotection or neuroprotection after APC \[[@CR41], [@CR42]\].

Inflammatory cytokines {#Sec6}
======================

Oxidative stress and inflammatory reactions contribute to I/R injury. In the ischemic phase, the balance of endogenous oxidants and antioxidants is disrupted, and pro-inflammatory cytokines like TNF-α, IL-1, and reactive oxygen species are largely produced in reperfusion phase. TNF-α and other pro-inflammatory cytokines cause further oxidative stress through inducing phosphorylation and the activation of nuclear factor κB (NF-κB). As a transcription factor, NF-κB is widely involved and regulates the expression of a large number of cytokines, chemokines and pro-inflammatory enzymes, such as TNF-α, IL1, IL8, iNOS, cyclooxygenase-2 and adhesion molecules, which are critical to generate inflammation and apoptosis \[[@CR43], [@CR44]\].

Volatile anesthetic-induced preconditioning has been reported to protect myocardium against I/R injury by attenuating the activation of NF-κB and thus subsequently suppress the expression of NF-κB-dependent inflammatory cytokines \[[@CR45]--[@CR47]\]. Wang et al. demonstrated in an in vivo coronary artery occlusion experiment that sevoflurane preconditioning attenuates the upregulation of NF-κB with its two subunits p50 and p65, and subsequently decreases the expression of inflammatory proteins TNF-α and intercellular adhesion molecule-1 (ICAM-1). Administration of the NF-κB inhibitor parthenolide (PTN) before or after exposure to sevoflurane abolished the benefit effect as reducing the infarct sizes \[[@CR48]\]. In another research study, using electrophoretic mobility shift assay, NF-κB activity was determined. After preconditioning with sevoflurane, NF-κB binding activity and activation were significantly downregulated, with reduced expression of TNF-α, ICAM-1, IL-1 and iNOS during myocardial I/R injury \[[@CR44]\].

In central nervous system, pathological conditions cause the overactivation of microglia, and a large quantity of pro-inflammatory cytokines can be subsequently released from activated microglia \[[@CR49], [@CR50]\]. Toll-like receptor 4 (TLR4) is expressed primarily in microglia and plays a key role in the activation of microglia and the production of inflammatory cytokines in central nervous system \[[@CR51]--[@CR53]\]. NF-κB has been confirmed as a downstream factor of TLR4 signaling pathway \[[@CR54], [@CR55]\], and similar to the research results in cardiovascular system, after activation, NF-ΚB moves to the nucleus, and triggers the transcription of genes responsible for inflammatory reactions and eventually lead to neuron damage. Moreover, TLR4/NF-κB signaling pathway also mediates the neuroprotective effect of APC. Sun et al. demonstrated in an in vitro OGD experiment with primary neurons/astrocytes culture that 2% isoflurane preconditioning has similar effects as the TLR4-specific inhibitor CLI-095: downregulated the expression of TLR4, IL-1ß, TNF-α, and up-regulated NF-κB inhibitor IκB-α \[[@CR56]\]. In vivo study of the same research group showed that isoflurane preconditioning attenuated neurological deficits, infarct volume against ischemic stroke, and inhibited microglial activation. Molecular tests also showed the same results as the in vitro study. There are also research reports demonstrating that sevoflurane provides direct neuroprotective effects in suppressing the activation of NF-kappa B and expression of inflammatory cytokines against focal ischemic brain injury \[[@CR57], [@CR58]\].

Apoptosis {#Sec7}
=========

Ischemia causes the destruction of cardiomyocytes and leads to necrosis. However, the infarct size of myocardium is determined not only by the necrosis after ischemia, but also the apoptotic cell death triggered and principally developed during the phase of reperfusion. Apoptosis is associated with the extension of infarction over the time of prolonged reperfusion, and has been considered as the predominant form of both myocardial and cerebral ischemia- and reperfusion-related cell death. The importance of apoptosis in cell death following reperfusion has been demonstrated in vivo; the results show that the level of apoptosis is dependent on the duration of reperfusion. Apoptosis can be triggered by ischemia but reperfusion accelerates the process \[[@CR59], [@CR60]\].

Several protein families are involved in apoptosis, including B cell lymphoma-2 (Bcl-2), Bax, Bak and caspases. Bcl-2 family is one of the most important regulatory factors in cell apoptosis. Because of its anti-apoptotic effect, the role of Bcl-2 family in APC-induced cardio- and neuroprotection has also been widely investigated \[[@CR61], [@CR62]\]. In myocardial I/R injury model, VAs were found to have anti-apoptotic effects as well as reduce myocardial infarct size. Raphael et al. demonstrated that isoflurane preconditioning attenuates infarct size and myocardial apoptosis after I/R, via PI3K/Akt signaling and modulation of anti-apoptotic Bcl-2 family proteins \[[@CR63]\]. Interestingly, evidence shows that, unlikely to the role of triggering the production of inflammatory cytokines, the activation of NF-kappa B is involved in upregulating anti-apoptotic protein Bcl-2 resulting in significant decrease in cell apoptosis and mediates cytoprotective effects \[[@CR64], [@CR65]\]. Furthermore, this mechanism was also consistent with the experimental results reported by Wang et al. in a study of APC with sevoflurane \[[@CR48]\]. Sevoflurane-produced myocardial protection during preconditioning was through upregulation of anti-apoptotic protein Bcl-2, and ultimately decreasing caspase-3 expression and apoptosis. This benefit effect was abolished by NF-kappa B inhibitor PTN.

Likewise, anti-apoptotic effect of APC was confirmed with neurons. Preconditioning with 2% sevoflurane or 1.5% isoflurane for 60 min provided neuroprotection by upregulation of anti-apoptotic genes (Aven, Bcl-2, Bcl2l2, and Prok2) and downregulation of pro-apoptotic genes (Tnf, Tnfrsf10b and Tp53) \[[@CR66]\]. A very recent in vivo study proved that APC with sevoflurane reduced apoptosis in rat brains, which was also associated with increased ratios of anti-apoptotic Bcl-2 family proteins, with decreased activation of JNK and p53 pathways, and finally decreased caspase-3 expression \[[@CR67]\]. Zhao et al. reported that isoflurane preconditioning at a clinically relevant concentration improved long-term neurological outcome in neonatal rats under hypoxic ischemic brain injury. This effect involved an increased expression of anti-apoptotic protein Bcl-2 \[[@CR68]\]. Sevoflurane preconditioning has been proved to show neuroprotective effects in terms of improving neurofunctional outcome and the attenuating infarct volume significantly. The anti-apoptotic effect was observed up to 7 days after cerebral I/R injury \[[@CR69]\]. PI3K/Akt signaling pathway and its downstream target GSK-3ß were implicated to be involved in caspase-dependent mechanisms of cell apoptosis \[[@CR70]\]. Ischemia injury induces Akt phosphorylation at Ser473, sevoflurane preconditioning inhibited the hyperphosphorylation in a MCAO model, which thereby phosphorylated/inactivated GSK-3ß and represented a neuroprotective effect \[[@CR71]\] (Fig. [1](#Fig1){ref-type="fig"}).

Cortical spreading depolarization {#Sec8}
=================================

Cortical spreading depolarization (CSD) is a relative newly discovered mechanism for secondary ischemic neurological damage. It appears that spreading depolarization does not have a physiological role in normal tissue but can be instigated under the pathological conditions, such as mechanical damages, noxious chemical agents, ischemia and propagates slowly across the cerebral cortex \[[@CR72], [@CR73]\]. In the last decade, more and more clinical studies showed that CSDs are correlated to a subsequent brain tissue injury, neurological deficits and worse patient outcome \[[@CR74]--[@CR76]\]. Takagaki et al. examined and compared the effects of isoflurane and propofol on CSDs in a rodent MCAO model and found out that isoflurane reduced the occurrence of CSDs significantly in comparison to propofol. Furthermore, cerebral blood flow and plasma glucose are significantly lower under the propofol suggesting a worse oxygen and glucose supply in propofol group \[[@CR77]\]. The hypothesis that VAs contribute to neuroprotection is further validated by the research group of Kudo et al. \[[@CR78]\]. Isoflurane achieved significant suppression of CSD frequency and CSD propagation speed.

Clinical aspects {#Sec9}
================

Accumulating clinical studies have confirmed the benefits of intraoperative administration of VAs in patients undergoing coronary artery bypass surgery \[[@CR79]--[@CR81]\]. A meta-analysis of randomized clinical trials involving 1922 patients undergoing cardiac surgery showed that, in comparison with total intravenous anesthesia (TIVA), desflurane and sevoflurane achieved significant reductions of myocardial infarctions \[2.4% in the VA group vs 5.1% in the TIVA group, odds ratio (OR) 0.51\] and all-cause mortality (0.4% vs 1.6%, OR 0.31). Besides these benefit effects, the use of VAs was also associated with a shorter duration of intensive care unit stay and need for mechanical ventilation \[[@CR82]\]. Isoflurane was reported to reduce troponin release in a randomized clinical trial involving forty-five patients undergoing elective off-pump coronary artery bypass surgery \[[@CR83]\]. Guerrero Orriach and colleagues found out that the use of sevoflurane attenuated significantly the postoperative levels of troponin I at 24 h and N-terminal pro-brain natriuretic peptide (NT--proBNP) at 24 and 48 h in coronary surgery patients. Furthermore, the use of inotropic drugs was also significantly reduced at 24 and 48 h postoperatively \[[@CR84]\]. Amr et al. demonstrated in a recent clinical trial with 45 patients undergoing coronary artery bypass graft surgery that preconditioning with isoflurane 2.5% improved significantly perioperative hemodynamic function, and reduced postoperative level of cardiac troponin I and creatine kinase isoenzyme MB (CK-MB) release \[[@CR85]\].

Based on experimental studies, VAs have shown promising results against cerebral ischemic injury. However, similar results in human trials are much less certain, clinic evidence is still very limited \[[@CR86], [@CR87]\]. Because of their vasodilative effect, VAs could lead to higher intracranial pressure; therefore, propofol still remains as the first choice of anesthetic for severe head trauma (SHT) or patients with elevated intracranial pressure (ICP) \[[@CR88]\]. But there are also studies demonstrating that sevoflurane has nearly no impact on cerebrovascular autoregulation and the ICP below 1.0 minimum alveolar concentration (MAC). These results make sevoflurane a possible choice for neurological surgeries \[[@CR89], [@CR90]\]. Schoen et al. reported that sevoflurane improved short-term postoperative cognitive function in patients undergoing on-pump cardiac surgery compared with propofol \[[@CR91]\]. Dabrowski et al. confirmed that \[[@CR92]\] sevoflurane and isoflurane attenuated plasma matrix metalloproteinase-9 (MMP-9), glial fibrillary acidic protein (GFAP) concentrations, which are considered to be the specific biochemical markers of brain injury \[[@CR93], [@CR94]\], and brain magnesium disorders in patients undergoing coronary artery bypass graft surgery. In addition, isoflurane was also reported capable of providing beneficial effects on regional cerebral blood flow in patients with subarachnoid hemorrhage, without any relevant elevation of ICP \[[@CR95]\]. Another very recent clinical study from neonatal intensive care unit (NICU) showed that, in patients with low ICP or only moderately elevated values, isoflurane was capable of reducing the in cerebral oxygen extraction without significant intracranial hypertension \[[@CR96]\], indicating a promising strategy of neuroprotection for patents in ICU or NICU. All these clinical research results suggest a promising prospect of VAs in cerebral protection for patients undergoing neurosurgical or non-neurosurgical procedures. However, there are also clinical studies with confusing results on VAs *vs* propofol in neurological surgeries. In a recent systemic clinic review and meta-analysis of Chui et al., VAs and propofol were compared for maintenance of anesthesia during craniotomy operations. Propofol and VAs did not show any significant differences in brain relaxation scores, but propofol-anesthesia maintained lower ICP and higher cerebral perfusion pressure (CPP) values. Postoperative complications were similar between two groups; however, postoperative nausea and vomiting were more associated with VA anesthesia \[[@CR97]\]. The similar conflicting evidences have also been reported in other clinical studies \[[@CR5], [@CR98]\] (Table [1](#Tab1){ref-type="table"}).Table 1Clinical studies of the protective effects of VAsSurgeryPatients and number (*n*)Volatile anesthetics and doseOutcomeRefs.CardioprotectionCardiopulmonary bypass*n* = 200Sevoflurane\
0.5--2%Increase of troponin I ↓\
Cardiac output ↑\
Inotropic support ↓\
Duration of stay in the ICU and hospital ↓De Hert et al. \[[@CR79]\]Cardiopulmonary bypassElderly high-risk^a^ patients, *n* = 45Sevoflurane\
0.5--2%\
Desflurane\
1--4%Decrease in cardiac index (CI) post-CPB ↓\
Inotropic support ↓De Hert et al. \[[@CR80]\]Off-pump coronary artery bypass grafting*n* = 48Sevoflurane\
1.0 MAC and 1.5 MACPost-surgical cardiac Troponin I ↓Wang et al. \[[@CR81]\]Off-pump coronary artery bypass*n* = 45Isoflurane\
1.0--2.5%Post-surgical cardiac index ↑\
Increase of troponin T ↓Tempe et al. \[[@CR83]\]Off-pump coronary artery bypass*n* = 60Sevoflurane\
0.7 and 1 MACIncrease of troponin I ↓\
Postoperative NT-proBNP^b^ ↓\
Inotropic support ↓Guerrero Orriach et al. \[[@CR84]\]On-pump coronary artery bypass*n* = 45Isoflurane 2.5%\
10 min^c^Hemodynamic recovery ↑\
Cardiac troponin T ↓\
CK-MB release ↓\
Inotropic support ↓Amr et al. \[[@CR85]\]Cerebral protectionCardiopulmonary bypass*n* = 128Sevoflurane\
0.6--1 MACCognitive function ↑Schoen et al. \[[@CR91]\]Cardiopulmonary bypass*n* = 92Sevoflurane\
0.5 MAC\
Isoflurane\
0.5 MACPostoperative Mg disorders ↓\
Increase in plasma MMP-9 and GFAP^d^ concentration ↓Dabrowski et al. \[[@CR92]\]*CPB* cardiopulmonary bypass, *MAC* minimal alveolar concentration^a^Elderly high-risk: older than 70 years with three-vessel disease and an ejection fraction less than 50% with impaired length-dependent regulation of myocardial function^b^N-terminal pro-brain natriuretic peptide^c^Preconditioning with a 10-min exposure to isoflurane 2.5% followed by 5-min washout^d^Sensitive marker of brain injury: matrix metalloproteinase-9 (MMP-9), glial fibrillary acidic protein (GFAP)

Not only in cerebral- and cardiac systems, anti-apoptotic effects of volatile anesthetic were also reported in hepatic ischemia--reperfusion injury \[[@CR99], [@CR100]\]. Treatment with sevoflurane significantly improved the pulmonary function of lung grafts by reducing levels of pro-inflammatory cytokines \[[@CR101]\]. Desflurane preconditioning demonstrated significant renal protective effects in a rabbit model of acute I/R injury \[[@CR102]\]. In a recent study with human volunteers, Lucchinetti et al. reported the protective effect of sevoflurane in human endothelium though the inhibition of leukocyte adhesion \[[@CR103]\]. In another randomized clinical trial with seventy-two patients undergoing coronary artery bypass graft surgery, preconditioning by sevoflurane reduced the transcript levels for platelet--endothelial cell adhesion molecule-1 (PECAM-1), indicating the protective effect on endothelial system, as well as attenuated significantly the incidence of late cardiac events during the first year after surgery comparing with the placebo group \[[@CR104]\]. It is well known that vascular endothelial function is critically involved in a broad range of diseases as well as ischemic--reperfusion injury \[[@CR105]--[@CR107]\]. Endothelial stability plays a key role in maintaining physical vascular function and coagulation status. Hence, VA preconditioning could be served as a ubiquitous 'multiorgan' protection through reducing endothelial dysfunction in I/R injury.

Conclusions {#Sec10}
===========

Extensive evidences from animal experimental studies have proved that VAs have beneficial effect to protect the myocytes and neurons from ischemia/reperfusion injury. The protective cellular signaling pathways are extremely similar in both cardiovascular and central nervous systems. There are also promising results from clinical trials with beneficial effects of APC for the patients undergoing cardiac and neurological surgeries. Some research results still remain confusing and conflicting, which could be, however, the results of different timing and patterns of administration, or inappropriate doses. Further work including more randomized and qualitative clinical trials is still required. Determining the time effect, the concentration of VAs during operations, and long-term clinic outcome should be focused to clarify and guarantee the best protective effects of VAs in clinical practice.
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